Thus, we hypothesize that reversible or more probably irreversible MAO inhibitors and H3R inverse agonists/antagonists can have overlapping pharmacological utilities, suggesting ligands, interacting with both targets, as promising candidates for treatment of neurodegenerative diseases. Here, HRH3 is linked to neurodegenerative disease.